Print this page
-
A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in
Subjects with Ovarian Cancer
Protocol: 052306Principal Investigator:
- Eugenia Girda Assistant Professor GYN (Rutgers University)
Applicable Disease Sites: Ovary -
Phase 1/Expansion Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma.
Protocol: 012312Principal Investigator:
- Yun Kyoung Tiger (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors
Protocol: 052305Principal Investigator:
- Eugenia Girda Assistant Professor GYN (Rutgers University)
Applicable Disease Sites: Other Female Genital -
A Phase II Multicenter, Open-Label, Single-Arm Dose Escalation Study of Asciminib Monotherapy in 2nd and 1st Line Chronic Phase Chronic Myelogenous Leukemia.
Protocol: 022304Principal Investigator:
- Neil Palmisiano MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Leukemia, other -
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease
Protocol: 012313Principal Investigator:
- Amer Assal MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Multiple Myeloma -
Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study.
Protocol: 012314Principal Investigator:
- Joanna Rhodes MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Lymphoid Leukemia